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Abstract:
Metallo-beta-lactamase production is an important mechanism for carbapenem resistance of Pseudomonas aeruginosa, which 
represents an emerging public health challenge. We report the case of a patient admitted to an intensive care unit, with sepsis 
caused by multidrug-resistant São Paulo Metallo-beta-lactamase-1-producing P. aeruginosa. This is the first case of infection by 
this pathogenic strain in the State of Mato Grosso do Sul, Brazil. Thus, infection control measures are required for preventing 
future spread and outbreaks.
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INTRODUCTION
Pseudomonas aeruginosa is a leading cause of nosocomial 
infections, particularly in intensive care units (ICUs). The 
prevalence of carbapenem resistance in these bacteria has been 
increasing worldwide, especially in Brazil1. The high frequency 
of genetic mutations that confer antibiotic resistance to these 
pathogens is a major concern in hospitals worldwide. The 
detection of multiple antimicrobial resistance determinants in 
these microorganisms is increasing. The production of metallo-
beta-lactamase (MβL) by P. aeruginosa strains is considered one 
of the most important factors conferring resistance to β-lactam 
antibiotics, including carbapenems2.
Several types of MβL have been identified among 
P. aeruginosa strains. Production of São Paulo metallo-beta-
lactamase (SPM) has been associated with broad-spectrum 
β-lactam resistance, including carbapenem resistance, and has 
been identified as the predominant MβL in Brazil1,3. SPM-1 
was first detected and reported in 2001 in São Paulo, Brazil1. 
Since then, SPM-1-producing P. aeruginosa strains have been 
reported in different regions of Brazil3,4. However, data are 
lacking regarding the clinical features of SPM-1-related drug 
resistance in the Central Western Brazilian State of Mato Grosso 
do Sul. Here, we report a multidrug-resistant P. aeruginosa 
strain producing SPM-1, which was isolated from a patient 
hospitalized in the ICU of a teaching hospital in the City of 
Dourados, Mato Grosso do Sul. The rapid identification of 
multidrug resistance is essential to prevent the spread of these 
microorganisms in hospitals, and to establish adequate therapies 
against this infection5.
CASE REPORT
In November 2014, a 57-year-old man was admitted to the 
ICU of a teaching hospital in the City of Dourados, Mato Grosso 
do Sul, a Central Western Brazilian state. The patient had been 
hospitalized for 6 days in another health facility where, owing 
to Fournier gangrene, he underwent a colostomy procedure and 
surgical debridement. The patient was admitted to our institution 
because of hemiplegia on the left side, which was caused by a 
previous stroke. He also displayed a low level of consciousness 
(Glasgow coma score of 6) and had a history of hypertension and 
diabetes. He was sedated and placed on mechanical ventilation 
via tracheostomy. On the day of admission, he underwent dialysis 
because of acute renal failure with suspicion of integument and 
urinary sepsis, which presented as lower limb edema and the discreet 
presence of debridement in the expansion region of the scrotum. 
He underwent procedures to introduce several invasive devices 
such as a central venous catheters, colostomy bag and urethral.
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After 34 days of hospitalization, P. aeruginosa was isolated 
from urine culture samples. Intravenous treatment, which 
included teicoplanin (600mg) once a day and meropenem 
(1,000mg) twice a day, was administered for 26 days. On the 
21st and 39th days of hospitalization, the patient experienced 
cardiopulmonary arrest without electrical activity or pulse; 
however, the medical staff managed to revive him. After 49 days 
of hospitalization, his condition had progressively worsened 
and P. aeruginosa was isolated from another urine sample. 
New antibiotic therapy was started with meropenem (500mg) 
and tigecycline (50mg) twice a day for 19 days. On the 60th 
day, the patient collapsed and experienced two heart attacks 
that progressed to death. The cause of death was reported as 
cardiorespiratory arrest aggravated by sepsis.
The P. aeruginosa strains were identified using the 
automated microbial testing system VITEK® 2 (bioMérieux, 
Marcy-l′Étoile, France) and confirmed by performing 
matrix-assisted laser desorption/ionization time of flight 
mass spectrometry (MALDI-TOF MS) using a Microflex LT 
spectrometer (Bruker Daltonics, Billerica, MA, USA)6. The 
minimal inhibitory concentrations (MICs) were determined 
using broth microdilution according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines7, except 
for tigecycline MICs, which were interpreted using the 
Food and Drug Administration guidelines8. P. aeruginosa 
showed sensitivity only to polymyxin B (MIC50 0.5µg/mL), 
colistin (MIC50 4µg/mL) and tigecycline (MIC50 0.5µg/mL). 
Two P. aeruginosa strains isolated had the same antimicrobial 
resistance profile.
Preliminary screening for the presence of carbapenemases 
was performed using the modified Hodge test according to CLSI 
guidelines7 and by ertapenem hydrolysis using MALDI-TOF 
MS9. The presence of genes encoding β-lactamase (blaIMP-1, 
blaKPC-2, blaNDM-1, blaVIM-1, blaOXA-48, blaGES-1, and blaSPM-1) was 
detected using polymerase chain reaction (PCR), followed by 
sequencing using specific primers as previously described6. The 
blaSPM-1 gene was present in the multidrug-resistant P. aeruginosa 
strains. The predicted protein sequence was analyzed using 
the Lasergene Software Package (DNASTAR, Madison, WI, 
USA) and compared to the sequences deposited in GenBank. 
The presence of blaIMP-1, blaNDM-l, blaVIM-1, blaOXA-48, and blaGES-1 
could not be confirmed. 
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DISCUSSION
The spread of carbapenemase-producing P. aeruginosa 
strains is alarming, because this species is a main source of 
hospital-acquired infections in critically ill patients, and is 
known for its ability to transfer drug resistance genes2. The 
dissemination of carbapenemase-producing strains is of great 
concern to public health services in Brazil. Several outbreaks 
and sporadic cases of SPM-1-producing strains, which spread 
rapidly, have been reported in Brazil10,11. However, to our 
knowledge, there have been no reports of SPM-1-producing 
P. aeruginosa strains in the State of Mato Grosso do Sul. 
Here, we report a case of a patient who died from uncontrolled 
infection complicated by sepsis and a urinary tract infection, 
which was originally caused by a multidrug-resistant SPM-1-
producing P. aeruginosa strain. The patient had not traveled to 
any other state in which these pathogens have been previously 
reported. However, he was exposed to risk factors associated 
with acquisition of MβL-producing bacteria, such as an ICU 
stay, extended hospitalization, history of comorbidity and the 
use of invasive devices9,11. This patient was not colonized at 
admission. His clinical history showed previous hospitalizations 
and surgical procedures before our initial culture was collected. 
However, this study was not able to identify the introduction 
of this strain into our hospital. Phenotypic test results were 
concordant with the detection of carbapenemase, and PCR and 
deoxyribonucleic acid (DNA) sequencing confirmed SPM-1-
producing P. aeruginosa.
The patient died after administration of two different 
antimicrobial therapies. The initial treatment consisted of a 
combination of teicoplanin and meropenem. However, this 
inappropriate therapy may have contributed to the worsening 
of his clinical condition and the evolution of sepsis. In vitro 
test results suggested that polymyxin B and colistin represent 
alternative therapies. Although these drugs may be associated 
with severe nephrotoxicity and there is a paucity of data on 
clinical outcomes, they are still used as the last therapeutic 
choice against P. aeruginosa infections12.
In this study, we confirmed the presence of SPM-1-
producing P. aeruginosa in Mato Grosso do Sul, a Central 
Western Brazilian state. This report highlights the potential 
emergence of these strains, and demonstrates the need for 
strategies to improve infection control measures that prevent an 
increase in these nosocomial infections. The rapid identification 
of resistance profiles of carbapenemase-producing strains is 
crucial for timely implementation of appropriate antimicrobial 
therapy.
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